Macrovascular disease in systemic sclerosis: The tip of an iceberg?

Rheumatology

Volumn 47, Issue SUPPL. 5, 2009, Pages

  Belch, J J F ^a   Mcswiggan, S ^a   Lau, C ^a  

^a NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Macrovascular disease; Systemic Sclerosis

Indexed keywords

ADRENOMEDULLIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPOPROTEIN A; OXIDIZED LOW DENSITY LIPOPROTEIN; VON WILLEBRAND FACTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONFERENCE PAPER; ENDOTHELIAL DYSFUNCTION; HUMAN; INCIDENCE; INFLAMMATION; KIDNEY DISEASE; MICROANGIOPATHY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; VASOSPASM;

EID: 69949163721     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken280     Document Type: Conference Paper

References (14)

1. Belch JJF. The clinical assessment of scleroderma spectrum disorders [Editorial]. Brit J Rheumatol 1993;32:353-6.
2. Altman RD, Medsger TA, Bloch DA et al. Predictors of survival in systemic sclerosis (Scleroderma). Arthritis Rheum 1991;34:403-13.
3. Hesselstrand R, Scheja A, Åkesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998;57:682-66.
4. Tashkin DP, Elashoff R, Clements PJ et al. cyclophosphamide versus placebo in scleroderma lung disease. New Engl J Med 2006;354:2655-66.
5. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis 1972-2002. Ann Rheum Dis 2007;66:940-944.
6. Bryan C, Howard Y, Brennan P, Black C, Silman A. Survival following the onset of scleroderma: Results from a retrospective inception cohort study of the UK patient population. Brit J Rheumatol 1996;35:1122-6.
7. Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Brit J Rheumatol 1998;37:750-5.
8. Candell-Riera J, Armadans-Gil L, Simeon C-P et al. Comprehensive non-invasive assessment of cardiac involvement in limited systemic sclerosis. Arthritis Rheum 1996;39:71138-45.
9. Bolad I, Delafontaine P. Endothelial dysfunction: Its role in hypertensive coronary disease. Curr Opin Cardiol 2005;20:270-4.
10. Mok MY, Cheung BMY, Lo Y, Leung RYH, Wong WS, Lau CS. Elevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis. J Rheumatol 2007;34:2224-9.
11. Veale DJ, Kirk G, McLaren M, Belch JJF. Clinical implications of soluble intercellular adhesion molecule-1 levels in a systemic disease - scleroderma. Brit J Rheumatol 1998;37:1227-9.
12. Hettema ME, Bootsma H, Kallenberg CJM. Macrovascular disease and atherosclerosis in SSc. Rheumatology 2008;47:578-83.
13. Dick EA, Aviv R, Francis I et al. Catheter angiography and angioplasty in patients with scleroderma. Br J Radiol 2001;74:1091-6.
14. Veale DJ, Belch JJF. Large vessel occlusive disease in systemic sclerosis. Ann Rheum Dis 1993;52:837-8.